STRO

#2800
Sutro Biopharma, Inc.
35.8000 USD
+6.58%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
35.6777
35.9500
Range Annuel
16.7400
36.0000
Changement quotidien
+6.58%
Changement Mensuel
+46.54%
Evolution sur 6 mois
+105.87%
Changement Annuel
+105.87%
Clôture Précédente
33.5900
Ouvrir
35.9500
Plus Bas
35.6777
High
35.9500
Volume
5
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 593.1071 M
  • Employee 137
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-0.51
ratio cours/chiffre d'affaires
0.96

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

Nouvelles